Clinical Trial Update: Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial evaluating imlunestrant plus abemaciclib in ER-positive, HER2-negative breast cancer, with Ki67-guided treatment decisions after 2 w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Abemaciclib (abemaciclib)
• Imlunestrant (imlunestrant)

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING